TOKEN2049
7.6.2022 08:39:13 CEST | Business Wire | Press release
TOKEN2049 , Asia’s premier crypto conference, has announced a number of high profile Title Sponsors for its much-anticipated Singapore debut. Taking place from 28-29 September 2022, this year’s event marks TOKEN2049’s first physical presence in Singapore, which will be held in conjunction with the Formula 1 Singapore Grand Prix 2022 , ahead of the race weekend.
As the flagship event of Asia Crypto Week , the conference is set to see over 3,000 attendees as they gather to learn from prominent thought leaders and innovators across the crypto industry, including the CEOs and founders of some of the world’s largest crypto-related projects. Over 130 sponsors and exhibitors have already confirmed their participation with numbers steadily rising as anticipation builds ahead of September.
“TOKEN2049 is shaping up well in bringing together the brightest minds of our ecosystem in exploring pathways of innovation and collaboration. As one of the leading enablers dedicated to unlocking the full potential of digital assets, we look forward to the dialogue and conversations at this gathering,” said Cynthia Wu, Founding Partner at Matrixport.
With this year’s agenda spanning institutional investment trends to the rise of the metaverse and Web3, the diversity of this year’s title sponsors for TOKEN2049 Singapore is a testament to a flourishing industry ecosystem. This includes Singapore-based crypto unicorn and digital assets financial services platform Matrixport; leading cryptocurrency exchange app and Formula 1 global partner Crypto.com; global leader in digital assets products and infrastructure Amber Group; revolutionary social currency $WHALE which is backed by one of the largest and most valuable NFT collections in the world; community-governed DeFi platform MantraDAO; and collaborative Web3 credential infrastructure Project Galaxy.
Celebrating the upcoming event, Raphael Strauch, Founder of TOKEN2049 said: “Within the past few months, the crypto ecosystem has seen a whirlwind of change and growth, and it’s only befitting that we’re gathering in Singapore — one of the region’s leading innovation hubs — to celebrate how far we’ve come.”
Alongside its impressive speaker line-up including Pantera Capital CEO Dan Morehead, Ava Labs CEO Emin Gün Sirer, Three Arrows Capital CIO and CEO Su Zhu. Additional title sponsors at the event include enterprise-grade crypto infrastructure company Fireblocks; cryptocurrency exchange and derivative trading platform Bitmex; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; decentralised and open-source platform Syscoin; Asia’s leading institutional digital asset custodian Hextrust; global online identity verification platform Trulioo; the blockchain platform TRON and the first official Ethereum Virtual Machine based on the EOS network Trust EVM.
“From our decorated bench of Title Sponsors to our speaker line-up, we’re thrilled to see continued support from so many of the industry’s leading organizations and are looking forward to spotlighting some of the most exciting, emerging voices across the ecosystem. We’ve seen tremendous interest from potential speakers and sponsors alike, and are thrilled to deliver a top-notch conference experience for all. To that end, we are very excited to be hosting a large closing party CÉ LA VI Singapore, on the rooftop deck of the Marina Bay Sands, overlooking the F1 Grand Prix track, with several notable European DJs flying in to grace the event,” continued Strauch.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
Raphael Strauch, Founder of TOKEN2049 is available for interview.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom